Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a partnership that will combine use of Immunophotonics’ lead asset, IP-001 and AngioDynamics’ ablation devices to explore the power of ablation in combination with immunotherapy for the treatment of solid tumor cancers. This collaborative effort extends to a partnership with the Cancer...
St. Louis cancer drug startup Immunophotonics Inc. will pursue expansion of its lead drug candidate through a partnership with the innovation arm of pharmaceutical giant Johnson & Johnson. (St. Louis INNO/Business Journal article)
Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a research collaboration with Johnson & Johnson Enterprise Innovation Inc. (JJEI) to explore the use of radiation in conjunction with Immunophotonics’ lead drug candidate, IP-001, as a novel immunotherapy approach for the treatment of solid tumor cancers. This collaboration agreement represents a...
Immunophotonics CEO Lu Alleruzzo announced, along with Dr. Robert CG Martin II, M.D, PhD, PACS, who serves as the Principal Investigator and National Coordinating Investigator at the University of Louisville, that the first patient has been dosed with IP-001 in the United States under Immunophotonics’ Investigational New Drug (IND) application with the FDA. The U.S....
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in a multinational clinical trial in France at Hôpital Foch in Suresnes. The protocol has been approved within the United States, United Kingdom, Switzerland, France, and Germany and will have over a dozen sites participating. The principal objective of this study is to...
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in Germany at SLK Kliniken Heilbronn GmbH. The patient was treated as part of a multinational clinical trial sponsored by Immunophotonics (IP-IIO-622) that will assess the safety and efficacy of its lead asset, IP-001. The protocol has been approved by regulatory authorities in...
Immunophotonics, Inc. has announced the recruitment and the dosing of its first patient in a multinational clinical trial in the United Kingdom at the University College London. This multinational clinical trial sponsored by Immunophotonics will assess the safety and efficacy of its lead asset, IP-001, and is currently enrolling patients for treatment of colorectal cancer,...
Immunophotonics has announced the FDA’s decision to allow the U.S. clinical trial of IP-001 to proceed with the enrollment of patients based on the company’s investigational new drug (IND) application. This extends the company’s INJECTABL-1 trial to the treatment of metastatic colorectal cancer, lung cancer, and sarcoma patients in the USA. Read more (Official Press...
Immunophotonics, Inc. announced the initiation of recruitment and the dosing of its first patient in a clinical trial assessing safety and efficacy of its lead asset, IP-001, in multiple solid tumor indications. This multinational clinical trial, denominated alternately as IP-IIO or INJECTABLE-1, is sponsored by Immunophotonics and will be enrolling patients for treatment of colorectal...
We are grateful to Johnson & Johnson Innovation for funding this vital work and are honored to advance medicine for our veterans and military community. This grant will provide Immunophotonics with the opportunity to expand the use of IP-001 into a previously untested combination with chemotherapy as a means of inducing systemic anti-tumor immune responses,...
